America Great Health

Safety Score

Market Cap $2.12M
Debt $2.41M
Cash $51.74K
EV $4.47M
FCF -$462.28K

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$877.65K
EBIT	-$520.65K
ROA	-156%
FCF	-$462.28K
Equity	-$4.80M
Growth Stability	1
PE	-2.41
PB	-0.44
P/FCF	-4.58
P/S	7.74
Price/Cash	0.02
Debt/Equity	-0.5
Debt/FCF	-5.21
Net Margins	-319%
Gross Margins	92%
Op. Margins	-190%
Sales Growth YoY	138%
Sales Growth QoQ	3%
Sales CAGR	-10%
Earnings Growth YoY	7%

Earnings Growth QoQ	-8%
Sales CAGR 5Y	83%
Earnings CAGR 3Y	1%
Sales CAGR 3Y	1%
Market Cap	$2.12M
Revenue	$273.71K
Assets	$333.39K
Total Debt	$2.41M
Cash	$51.74K
Shares Outstanding	21.17B
EV	4.47M
Safety Score	37%
Working Capital	-2.99M
Current Ratio	0.08
Gross Profit	$253.05K
Shares Growth 3y	1%
Equity Growth QoQ	2%
Equity Growth YoY	12%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

America Great Health operates as a biotechnology company. The company focuses on protein and peptide small molecular drugs research and development, diagnostic and medical devices with AI cloud computing, cell therapy, and regenerative medicine and supplements, as well as invests in technologies and integrates with business development for the healthcare ecosystem.

SEC Filings

Direct access to America Great Health (AAGH) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Mar 31
2023
- 10-Q Dec 31
- 10-Q Sep 30
- 10-K Jun 30
- 10-Q Mar 31
2022
- 10-Q Dec 31
- 10-Q Sep 30
- 10-K Jun 30
- 10-Q Mar 31

Sector Comparison

How does America Great Health compare to its competitors?

Not enough data to generate a comparison chart between America Great Health and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of America Great Health compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

America Great Health Discounted Cash Flow

Fully customizable DCF calculator online for America Great Health.

Years

Calculation mode

= -$4.6M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$462K	-$462K	-$462K	-$462K	-$462K	-$462K	-$462K	-$462K	-$462K	-$462K	-$462K	-$4.6M
DCF		-$420K	-$382K	-$347K	-$316K	-$287K	-$261K	-$237K	-$216K	-$196K	-$178K	-$1.8M
Value	-$4.6M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	06/2015	06/2016	06/2017	06/2018	06/2019	06/2020	06/2021	06/2022	06/2023	TTM
Net Margins	-1K%	-36%	-	-	-	-948%	-138%	-5K%	-380%	-319%
ROA	-	-	-	-444%	-46K%	-1K%	-39%	-1K%	-165%	-156%
ROE	-	105%	2K%	55%	39%	24%	58%	130%	17%	-

Bad Net Margins (-318.98%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	06/2015	06/2016	06/2017	06/2018	06/2019	06/2020	06/2021	06/2022	06/2023	TTM
Debt over FCF	-	-	-	-	-	-	-1.7	-0.94	-2.8	-5.21
Debt over Equity	-	-	-	-	-	-0	-1.24	-0.37	-0.5	-0.5
Growth Stability	-	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-5.21)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (-0.5)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	06/2015	06/2016	06/2017	06/2018	06/2019	06/2020	06/2021	06/2022	06/2023	CAGR 5Y
Revenue YoY growth	-	7K%	-100%	-	-	-	3K%	-47%	95%	83%
Earnings YoY growth	-	79%	-16%	-94%	10%	-20%	418%	2K%	-84%	-
Equity YoY growth	-	10%	-96%	124%	56%	28%	118%	713%	17%	-
FCF YoY growth	-	-	-	-	-	-	764%	338%	-47%	-